336 related articles for article (PubMed ID: 7648393)
1. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
2. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
Weber DA; Evavold BD; Jensen PE
Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
[TBL] [Abstract][Full Text] [Related]
3. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
4. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
5. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
8. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
9. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion.
vogt AB; Moldenhauer G; Hämmerling GJ; Kropshofer H
Immunol Lett; 1997 Jun; 57(1-3):209-11. PubMed ID: 9232453
[TBL] [Abstract][Full Text] [Related]
10. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
11. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.
Denzin LK; Hammond C; Cresswell P
J Exp Med; 1996 Dec; 184(6):2153-65. PubMed ID: 8976171
[TBL] [Abstract][Full Text] [Related]
12. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
13. Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
[TBL] [Abstract][Full Text] [Related]
14. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
16. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
17. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
18. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
[TBL] [Abstract][Full Text] [Related]
19. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]